IPAMORELIN
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it one of the safer GH secretagogues with minimal off-target hormonal effects. This educational protocol presents a once-daily subcutaneous approach using practical dilution for precise insulin-syringe measurements.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe. EACH
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once-daily regimen based on clinical trial designs.
Goal: Stimulate endogenous growth hormone release to support anabolic processes related to muscle growth, fat metabolism, and tissue repair.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired), followed by a 2–4 week pause to re-sensitize receptors.
Dose Range: 100–300 mcg daily with gradual titration; 200 mcg is a common middle-of-the-road dose.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within ~4 weeks.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
Target: 200–250 mcg daily by Weeks 5–12.
Frequency: Once per day (subcutaneous), ideally 30–60 minutes before bedtime.
Cycle Length: 8–12 weeks; optional extension to 16 weeks, followed by 2–4 week off-cycle.
Timing: Evening bedtime dosing preferred; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Ipamorelin has a short half-life (~1.5–2.5 hours); consistent daily timing maximizes effects.
How This Works
Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2–3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms, though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors, with preclinical and clinical studies showing it can accelerate gastric emptying
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic processes
Enhances fat metabolism and supports favorable body composition changes over time
High selectivity for GH release with minimal impact on other hormones (ACTH, cortisol, prolactin)
May support improved gastric motility and digestive function
Generally well tolerated with a low incidence of side effects at typical doses.
Occasional mild injection-site reactions (redness, swelling) may occur; very rare reports of water retention or increased hunger.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Pair with a balanced, protein-adequate diet to support muscle synthesis and recovery.
Combine resistance training and cardiovascular exercise to maximize anabolic and metabolic benefits.
Prioritize 7–9 hours of quality sleep nightly, as GH naturally peaks during deep sleep phases.
Manage stress levels, as chronic stress and elevated cortisol can blunt GH response.
Inject on an empty stomach (avoid food 2–3 hours before and 30–60 minutes after) to optimize GH release.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean your hands and work on a clean surface.
Swab the vial’s rubber stopper and injection site with alcohol; allow to dry.
Draw the calculated dose into the insulin syringe, eliminating air bubbles.
Suitable SC injection areas include the abdomen (2 inches from navel), outer thighs, upper outer arms, or flank/hip area.
Pinch a fold of skin between thumb and forefinger; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
After injection, release the pinched skin and withdraw the needle at the same angle.
Apply gentle pressure with a clean cotton or alcohol pad; do not rub vigorously.
Rotate sites systematically with each dose to prevent irritation or tissue damage.
Immediately dispose of the used syringe in a proper sharps container.
